The Antidote: Inside the World of New Pharma (69 page)

(
pp. 178
–82) Interviews with Eric Olson, Virginia Carnahan, Paul Negulescu, Peter Mueller, Sabine Hadida, and Ken Boger. Kate Kelly, “Inside the Fall of Bear Stearns,”
Wall Street Journal
, May 9, 2009; “Vertex Achieves Breakthrough in Treating Basic CF Defect,”
Commitment
(news publication of the Cystic Fibrosis Foundation), Spring 2008.

(
pp. 182
–84) Interviews with Josh Boger, Peter Mueller, Ann Kwong, John Alam, Bob Kauffman, Jack Weet, and Ken Boger. “Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C,”
Drugs.com
Mednews
, April 25, 2008; “Hepatitis C Drug Development Projects That Have Been Terminated, Transferred to Other Companies or for Which Information Is No Longer Available,”
http://www.hcvdrugs.com
, August 3, 2009.

(
pp. 184
–87) Interviews with Matt Emmens, Josh Boger, and Ian Smith. Andrew Pollack, “Genentech Rejects Takeover Bid from Roche,”
New York Times
, August 14, 2008; “ ‘Standstill’ Agreements Limit Potential Buyout Deals,”
IN VIVO
, September 11, 2008; Andrew Ross Sorkin, “Lehman Files for Bankruptcy; Merrill Is Sold,”
New York Times
, September 15, 2008; Luke Timmerman, “Vertex Sells Royalty Rights to HIV Drugs, Bets on Hepatitis C,” Xconomy, June 3, 2008; Elizabeth Bumiller and Jeff Zeleny, “First Debate Up in Air as McCain Steps Off the Trail,”
New York Times
, September 24, 2008.

(
pp. 187
–91) Interviews with Josh Boger and Matt Emmens. Matt Emmens and Beth Kephart,
Zenobia: The Curious Book of Business
, Berrett-Koehler Publishers, 2008.

(
pp. 192
–95) Interview with Josh Boger. Ron Winslow, “Investor Prospects Look Grim,”
Wall Street Journal
, January 12, 2009; Luke Timmerman, “Vertex CEO Josh Boger Retiring in May; Matthew Emmens to Fill Role,” Xconomy, February 5, 2009. The Boger-Huckman interview can be viewed online,
http://video.cnbc.com/gallery/?video=996324419
.

(
pp. 195
–98) Interviews with Josh Boger, Judy Lippke, Matt Fitzgibbon, Mark Murcko, Bink Garrison, Geoff Porges, and Ian Smith. Andrew Ross Sorkin and Duff Wilson, “Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth,”
New York Times
, January 26, 2009; Catherine Arnst, “Pfizer-Wyeth Merger Isn’t the Cure-All,”
BusinessWeek
, January 24, 2009; Mark Murcko, “This is a test,” email to his colleagues, February 6, 2009, by author’s permission.

(
pp. 198
–200) Interviews with Matt Emmens, Ian Smith, Michael Partridge, and Josh Boger. Todd Wallack, “Vertex Feeling Growing Pains: Firm Scrambles for Workers, Space as Drug Shows Promise,”
Boston Globe
, November 2, 2007; Luke Timmerman, “Vertex Raises $320 Million in Secondary Stock Offering,” Xconomy, February 19, 2009; Luke Timmerman, “Out with Hedge Funds, In with Blue Bloods,” Xconomy, February 20, 2009; Natasha Singer, “Merck to Buy Schering-Plough for $41 Billion,”
New York Times
, March 10, 2009; Toni Clarke, “Vertex Out-Foxes Big Pharma to Buy ViroChem,”
Forbes.com
, March 4, 2009; Andrew Pollack, “Roche Agrees to Buy Genentech for $46.8 Billion,”
New York Times
, March 13, 2009; “Biotech Could Follow Pharma’s M&A Lead,”
Investor’s Business Daily
, March 20, 2009.

(
pp. 200
–5) Interviews with Jack Weet, Matt Emmens, Peter Mueller, Josh Boger, Bink Garrison, and Amit Sachdev. The BIO podcast of Boger and Greenwood discussing the industry perspective can be heard online at
http://www.bio.org/articles/bio-leaders-joshua-boger-and-jim-greenwood-discuss-challenges-and-opportunities-biotech-ind
; “Consequences of Hepatitis C Virus: Costs of a Baby-Boomer Epidemic of Liver Disease,” Milliman, Inc., May 2009; Peter Baker, “Obama Was Pushed by Drug Industry, E-Mails Suggest,”
New York Times
, June 8, 2012.

(
pp. 205
–7) Interviews with Bink Garrison, Mark Murcko, Ann Kwong, and Matt Emmens.

(
pp. 207
–9) Interviews with Jack Weet, Ann Kwong, and Tara Kieffer. Andrew Pollack, “FDA Warning Is Issued on Anemia Drug’s Overuse,”
New York Times
, March 10, 2007.

(
pp. 209
–14) Interviews with Matt Emmens, Nancy Wysenski, Bink Garrison, and Adam Koppel. Robert Langreth, “Hard to Swallow,”
Forbes.com
, May 13, 2002; SEC Form 8-K for Endo Pharamaceuticals Holdings Inc., August 31, 2009 (Changes in Directors or Principal Officer, Financial Statements); “2009 Exits/Financings Deal of the Year Nominee: Vertex’s Milestone Sale,”
IN VIVO
, December 16, 2009; Adam Feuerstein, “Vertex Raising Money—Again! Biobuzz,” TheStreet, December 2, 2009.